Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Genenta Science SpA ADR (GNTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: GNTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $28.03
1 Year Target Price $28.03
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.04% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 63.28M USD | Price to earnings Ratio - | 1Y Target Price 28.03 |
Price to earnings Ratio - | 1Y Target Price 28.03 | ||
Volume (30-day avg) 1 | Beta 0.62 | 52 Weeks Range 2.74 - 7.28 | Updated Date 08/15/2025 |
52 Weeks Range 2.74 - 7.28 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.84% | Return on Equity (TTM) -54.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 48455712 | Price to Sales(TTM) - |
Enterprise Value 48455712 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -11.48 | Shares Outstanding 18289900 | Shares Floating 11223393 |
Shares Outstanding 18289900 | Shares Floating 11223393 | ||
Percent Insiders 39.15 | Percent Institutions 10.38 |
Upturn AI SWOT
Genenta Science SpA ADR
Company Overview
History and Background
Genenta Science S.p.A. ADR was founded in 2014 and is a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell (HSPC) gene therapy for cancer. It is headquartered in Milan, Italy. Their approach is based on the delivery of oncolytic viral payloads directly into tumor microenvironment to drive tumor specific immune response.
Core Business Areas
- Gene Therapy Development: Development of Temferon, an HSPC gene therapy platform for solid tumors and other applications. Focus on early-stage clinical trials and preclinical research.
Leadership and Structure
The company is led by a management team with expertise in biotechnology, oncology, and gene therapy. The organizational structure includes research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- Temferon: Temferon is Genenta's lead product candidate, an autologous cell therapy that genetically modifies patients' hematopoietic stem cells to express interleukin-12 (IL-12) in the tumor microenvironment. It's in early clinical trials for Glioblastoma Multiforme and other solid tumors. Market share is currently N/A as the product is still in clinical development. Competitors include companies developing other immuno-oncology therapies and gene therapies for cancer (e.g., CAR-T cell therapies, oncolytic viruses).
Market Dynamics
Industry Overview
The gene therapy market is a rapidly growing field within the pharmaceutical industry, driven by advancements in gene editing technologies and increasing demand for personalized medicine. The market is competitive, with several companies developing gene therapies for various diseases.
Positioning
Genenta Science is positioned as an innovator in HSPC gene therapy for cancer, with a focus on modulating the tumor microenvironment to enhance anti-tumor immune responses. Their competitive advantage lies in their proprietary technology platform and their focus on difficult-to-treat cancers.
Total Addressable Market (TAM)
The TAM for gene therapy in oncology is estimated to be in the billions of dollars and is expected to grow substantially over the next decade. Genenta Science is positioned to capture a share of this market with its novel approach to cancer immunotherapy.
Upturn SWOT Analysis
Strengths
- Innovative HSPC gene therapy platform
- Strong intellectual property portfolio
- Experienced management team
- Focus on unmet medical needs in oncology
Weaknesses
- Early-stage clinical development
- Limited financial resources
- Reliance on strategic partnerships
- High regulatory hurdles
Opportunities
- Expansion of Temferon to other solid tumors
- Strategic collaborations with pharmaceutical companies
- Advancements in gene editing technologies
- Increasing investment in gene therapy
Threats
- Competition from established pharmaceutical companies
- Regulatory setbacks
- Clinical trial failures
- Financial market volatility
Competitors and Market Share
Key Competitors
- BMY
- PFE
- NVS
- MRNA
Competitive Landscape
Genenta Science competes with larger pharmaceutical companies and biotechnology firms in the immuno-oncology and gene therapy space. Their advantage lies in their novel HSPC gene therapy platform, but they face challenges in terms of funding and market access.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily related to research and development advancements and clinical trial progress.
Future Projections: Future growth is dependent on the successful development and commercialization of Temferon and other pipeline products. Analyst estimates will vary.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Temferon, strategic collaborations, and expansion of the intellectual property portfolio.
Summary
Genenta Science SpA ADR is an early-stage biotech company with an innovative gene therapy platform for cancer. Their lead product, Temferon, is in clinical trials and shows promise. They face challenges related to funding, regulatory hurdles, and competition from larger companies. Their strengths are their novel technology and focus on unmet medical needs. The company needs to ensure steady funding is secured for its programs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry News
- Third Party Financial Data Providers
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genenta Science SpA ADR
Exchange NASDAQ | Headquaters Milan, MI, Italy | ||
IPO Launch date 2021-12-15 | Co-Founder, Chairman, CEO & GM Mr. Pierluigi Paracchi | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.genenta.com |
Full time employees 13 | Website https://www.genenta.com | ||
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.